The practical application and interpretation of simple lung function tests in cystic fibrosis

Ramsey B.W. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1998; 335: 179–88.

Bush A. Cardiopulmonary physiology. In: Hodson M.E. , Geddes D.M. , eds. Cystic Fibrosis. London: Chapman & Hall, 1995: 151–77.

Quanjer PhHed. Standardized lung function testing. Bulletin European de Physiopathologie Respiratoire 1983; 19(Suppl. 5): 7–92.

Brand P.L.P. The practical interpretation of lung function tests in asthma. Recent Advances in Pediatrics 1999; 18(in press).

Brand P.L.P. , Quanjer P.H. , Postma D.S. Interpretation of bronchodilator response in patients with obstructive airways disease. Thorax 1992; 47: 429–36.

Waalkens H.J. , Merkus P.J.F.M. , van Essen-Zandvliet E.E.M. Assessment of bronchodilator response in children with asthma. Eur Respir J 1993; 6: 645–51.

Taylor M.R.H. Asthma: audit of peak flow rate guidelines for admission and discharge. Arch Dis Child 1994; 70: 432–4.

Miller M.R. , Pincock A.C. Predicted values: how should we use them? Thorax 1988; 43: 265–7.

American Thoracic Society. Standardization of spirometry—1994 update. Am J Respir Crit Care Med 1995; 152: 1107–36.

Quanjer P.H. , Lebowitz M.D. , Gregg I. , Miller M.R. , Pedersen O.F. Peak expiratory flow; conclusions and recommendations of a working party of the European Respiratory Society. Eur Respir J 1997; 10(Suppl. 24): 2S–8S.

Redline S. , Wright E.C. , Kattan M. , Kercsmar C. , Weiss K. Short-term compliance with peak flow monitoring: results from a study of inner city children with asthma. Pediatr Pulmonol 1996; 21: 203–10.

Studnicka M. , Frischer T. , Neumann M. Determinants of reproducibility of lung function tests in children aged 7 to 10 years. Pediatr Pulmonol 1997; 25: 238–43.

Nickerson B.G. , Lernen R.J. , Gerdes C.B. Within-subject variability and per cent change for significance of spirometry in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis 1980; 122: 855–9.

Braggion C. , Pradal U. , Mastella G. , Coates A.L. , Milic-Emili J. Effect of different inspiratory maneuvers on FEV, in patients with cystic fibrosis. Chest 1996; 110: 642–7.

Koller D.Y. , Nilsson M. , Enander I. , Venge P. , Eichler I. Serum eosinophil cationic protein, eosinophil protein X and eosinophil peroxidase in relation to pulmonary function in cystic fibrosis. Clin Exp Allergy 1998; 28: 241–8.

Wojnarowski C. , Eichler I. , Gartner C. , Götz M. , Koller D.Y. , Frischer T. Sensitization to Aspergillus fumigatus and lung function in children with cystic fibrosis. Am J Respir Crit Care Med 1997; 155: 1902–7.

Hoiby N. , Koch C. Pseudomonas aeruginosa infection in cystic fibrosis and its management (Cystic fibrosis 1). Thorax 1990; 45: 881–4.

Frederiksen B. , Koch C. , Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330–5.

Mahadeva R. , Webb K. , Westerbeek R.C. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ 1998; 316: 1771–5.

Littlewood J.M. , Conway S.P. Cystic fibrosis in children and adults. A method of management (revised edition). Leeds: St James's & Seacroft University Hospitals, 1997.

Milla C.E. , Warwick W.J. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 1998; 113: 1230–4.

Gurney J.W. , Habbe T.G. , Hicklin J. Distribution of disease in cystic fibrosis; correlation with pulmonary function. Chest 1997; 112: 357–62.

Hoiby N. Isolation and treatment of cystic fibrosis patients with lung infections caused by Pseudomonas (Burkholderia cepacia) and multiresistant Pseudomonas aeruginosa. Neth J Med 1995; 46: 280–7.

Webb A.K. , Govan J.R. Burkholderia cepacia: another twist and a further threat. Thorax 1998; 53: 333–4.

Vu-Thien H. , Moissenet D. , Valcin M. , Dulot C. , Tournier G. , Garbarg-Chenon A. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosidans in a cystic fibrosis center. Eur J Clin Microbiol Infect Dis 1996; 15: 876–9.

Cheng K. , Smyth R.L. , Govan J.R. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996; 348: 639–42.

Ledson M.J. , Gallagher M.J. , Corkill J.E. , Hart C.A. , Walshaw M.J. Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia. Thorax 1998; 53: 432–6.

Clausen J.L. Lung volume equipment and infection control. ERS/ATS workshop report series. European Respiratory Society/American Thoracic Society. Eur Respir J 1997; 10: 1927–32.

Kirk Y.L. , Kendall A.K. , Ashworth H.A. , Hunter P.R. Laboratory evaluation of a filter for the control of cross-infection during pulmonary function testing. J Hosp Infect 1992; 20 193–8.

Leeming J.P. , Pryce-Roberts D.M. , Kendrick A.H. , Smith E.C. The efficacy of filters used in respiratory function apparatus. J Hosp Infect 1995; 31: 205–10.

Marchant J. , Bush A. Prevention of cross infection during outpatient spirometry. Arch Dis Child 1995; 72: 156–8.

Brand P.L.P. , Kerstjens H.A.M. , Postma D.S. Long-term multicentre trial in chronic non-specific lung disease. Methodology and baseline assessment in adult patients. Eur Respir J 1992; 5: 21–31.

Brand PLP, Kerstjens HAM, Postma DS, Dutch CNSLD Study Group. Long term clinical trials in obstructive lung disease: principles and practice. Pharmaceutical Medicine 1992; 5: 263–89.